Concurrent paclitaxel/cisplatin with thoracic radiation in patients with stage IIIA/B non-small cell carcinoma of the lung

S. J. Antonia, Henry Wagner Jr., C. Williams, M. Alberts, D. Hubbell, L. Robinson, J. Hilstro, J. C. Ruckdeschel

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

Nine patients with stage IIIB non-small cell lung cancer were entered into a phase II trial designed to determine the feasibility of giving a combination of paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) plus cisplatin concurrent with thoracic radiation. Paclitaxel was given as a 24-hour infusion (135 mg/m2) followed by cisplatin (75 mg/m2) every 4 weeks, for a total of four cycles. Thoracic radiation was given concurrently with the first two cycles of chemotherapy, for a total dose of 64.8 Gy over 6 weeks. Neutropenia and esophagitis were the most common toxicities, with 66% of patients experiencing grade 3 or 4 neutropenia and 55% experiencing grade 3 or 4 esophagitis. Grade 3 pulmonary toxicity developed in 33% of patients. All patients were able to receive the full dose of radiation, although half of the patients required some modification of the chemotherapy regimen. There was one complete response and four partial responses, yielding a 56% overall response rate. This study demonstrates that it is feasible to treat patients with stage IIIB non-small cell lung cancer with paclitaxel/cisplatin plus concurrent thoracic radiation, with a degree of toxicity comparable with that associated with other concurrent combined-modality regimens for this disease.

Original languageEnglish (US)
Pages (from-to)34-37
Number of pages4
JournalSeminars in oncology
Volume22
Issue number4 SUPPL. 9
StatePublished - Sep 4 1995

Fingerprint

Non-Small Cell Lung Carcinoma
Thorax
Radiation
Paclitaxel
Esophagitis
Neutropenia
Cisplatin
Drug Therapy
TP protocol
Lung

All Science Journal Classification (ASJC) codes

  • Hematology
  • Oncology

Cite this

Antonia, S. J., Wagner Jr., H., Williams, C., Alberts, M., Hubbell, D., Robinson, L., ... Ruckdeschel, J. C. (1995). Concurrent paclitaxel/cisplatin with thoracic radiation in patients with stage IIIA/B non-small cell carcinoma of the lung. Seminars in oncology, 22(4 SUPPL. 9), 34-37.
Antonia, S. J. ; Wagner Jr., Henry ; Williams, C. ; Alberts, M. ; Hubbell, D. ; Robinson, L. ; Hilstro, J. ; Ruckdeschel, J. C. / Concurrent paclitaxel/cisplatin with thoracic radiation in patients with stage IIIA/B non-small cell carcinoma of the lung. In: Seminars in oncology. 1995 ; Vol. 22, No. 4 SUPPL. 9. pp. 34-37.
@article{7d1c0d7dd0a94d85a1020c35a4eb172e,
title = "Concurrent paclitaxel/cisplatin with thoracic radiation in patients with stage IIIA/B non-small cell carcinoma of the lung",
abstract = "Nine patients with stage IIIB non-small cell lung cancer were entered into a phase II trial designed to determine the feasibility of giving a combination of paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) plus cisplatin concurrent with thoracic radiation. Paclitaxel was given as a 24-hour infusion (135 mg/m2) followed by cisplatin (75 mg/m2) every 4 weeks, for a total of four cycles. Thoracic radiation was given concurrently with the first two cycles of chemotherapy, for a total dose of 64.8 Gy over 6 weeks. Neutropenia and esophagitis were the most common toxicities, with 66{\%} of patients experiencing grade 3 or 4 neutropenia and 55{\%} experiencing grade 3 or 4 esophagitis. Grade 3 pulmonary toxicity developed in 33{\%} of patients. All patients were able to receive the full dose of radiation, although half of the patients required some modification of the chemotherapy regimen. There was one complete response and four partial responses, yielding a 56{\%} overall response rate. This study demonstrates that it is feasible to treat patients with stage IIIB non-small cell lung cancer with paclitaxel/cisplatin plus concurrent thoracic radiation, with a degree of toxicity comparable with that associated with other concurrent combined-modality regimens for this disease.",
author = "Antonia, {S. J.} and {Wagner Jr.}, Henry and C. Williams and M. Alberts and D. Hubbell and L. Robinson and J. Hilstro and Ruckdeschel, {J. C.}",
year = "1995",
month = "9",
day = "4",
language = "English (US)",
volume = "22",
pages = "34--37",
journal = "Seminars in Oncology",
issn = "0093-7754",
publisher = "W.B. Saunders Ltd",
number = "4 SUPPL. 9",

}

Antonia, SJ, Wagner Jr., H, Williams, C, Alberts, M, Hubbell, D, Robinson, L, Hilstro, J & Ruckdeschel, JC 1995, 'Concurrent paclitaxel/cisplatin with thoracic radiation in patients with stage IIIA/B non-small cell carcinoma of the lung', Seminars in oncology, vol. 22, no. 4 SUPPL. 9, pp. 34-37.

Concurrent paclitaxel/cisplatin with thoracic radiation in patients with stage IIIA/B non-small cell carcinoma of the lung. / Antonia, S. J.; Wagner Jr., Henry; Williams, C.; Alberts, M.; Hubbell, D.; Robinson, L.; Hilstro, J.; Ruckdeschel, J. C.

In: Seminars in oncology, Vol. 22, No. 4 SUPPL. 9, 04.09.1995, p. 34-37.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Concurrent paclitaxel/cisplatin with thoracic radiation in patients with stage IIIA/B non-small cell carcinoma of the lung

AU - Antonia, S. J.

AU - Wagner Jr., Henry

AU - Williams, C.

AU - Alberts, M.

AU - Hubbell, D.

AU - Robinson, L.

AU - Hilstro, J.

AU - Ruckdeschel, J. C.

PY - 1995/9/4

Y1 - 1995/9/4

N2 - Nine patients with stage IIIB non-small cell lung cancer were entered into a phase II trial designed to determine the feasibility of giving a combination of paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) plus cisplatin concurrent with thoracic radiation. Paclitaxel was given as a 24-hour infusion (135 mg/m2) followed by cisplatin (75 mg/m2) every 4 weeks, for a total of four cycles. Thoracic radiation was given concurrently with the first two cycles of chemotherapy, for a total dose of 64.8 Gy over 6 weeks. Neutropenia and esophagitis were the most common toxicities, with 66% of patients experiencing grade 3 or 4 neutropenia and 55% experiencing grade 3 or 4 esophagitis. Grade 3 pulmonary toxicity developed in 33% of patients. All patients were able to receive the full dose of radiation, although half of the patients required some modification of the chemotherapy regimen. There was one complete response and four partial responses, yielding a 56% overall response rate. This study demonstrates that it is feasible to treat patients with stage IIIB non-small cell lung cancer with paclitaxel/cisplatin plus concurrent thoracic radiation, with a degree of toxicity comparable with that associated with other concurrent combined-modality regimens for this disease.

AB - Nine patients with stage IIIB non-small cell lung cancer were entered into a phase II trial designed to determine the feasibility of giving a combination of paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) plus cisplatin concurrent with thoracic radiation. Paclitaxel was given as a 24-hour infusion (135 mg/m2) followed by cisplatin (75 mg/m2) every 4 weeks, for a total of four cycles. Thoracic radiation was given concurrently with the first two cycles of chemotherapy, for a total dose of 64.8 Gy over 6 weeks. Neutropenia and esophagitis were the most common toxicities, with 66% of patients experiencing grade 3 or 4 neutropenia and 55% experiencing grade 3 or 4 esophagitis. Grade 3 pulmonary toxicity developed in 33% of patients. All patients were able to receive the full dose of radiation, although half of the patients required some modification of the chemotherapy regimen. There was one complete response and four partial responses, yielding a 56% overall response rate. This study demonstrates that it is feasible to treat patients with stage IIIB non-small cell lung cancer with paclitaxel/cisplatin plus concurrent thoracic radiation, with a degree of toxicity comparable with that associated with other concurrent combined-modality regimens for this disease.

UR - http://www.scopus.com/inward/record.url?scp=0029050147&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029050147&partnerID=8YFLogxK

M3 - Article

C2 - 7644926

AN - SCOPUS:0029050147

VL - 22

SP - 34

EP - 37

JO - Seminars in Oncology

JF - Seminars in Oncology

SN - 0093-7754

IS - 4 SUPPL. 9

ER -